Needham & Company LLC Reaffirms Buy Rating for Hologic (HOLX)
Needham & Company LLC reiterated their buy rating on shares of Hologic (NASDAQ:HOLX) in a research note issued to investors on Tuesday, MarketBeat reports. Needham & Company LLC currently has a $50.00 price target on the medical equipment provider’s stock, up from their previous price target of $48.00.
A number of other research firms have also weighed in on HOLX. Bank of America raised Hologic from a neutral rating to a buy rating and set a $50.00 price objective for the company in a research report on Thursday, January 4th. Piper Jaffray Companies reaffirmed a buy rating and set a $48.00 price objective on shares of Hologic in a research report on Thursday, November 9th. Evercore ISI started coverage on Hologic in a research report on Wednesday, January 3rd. They set an outperform rating and a $50.00 price objective for the company. Royal Bank of Canada reaffirmed a hold rating and set a $42.00 price objective on shares of Hologic in a research report on Friday, September 22nd. Finally, Jefferies Group reaffirmed a buy rating and set a $44.00 price objective (down previously from $49.00) on shares of Hologic in a research report on Tuesday, October 10th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of $48.79.
Hologic (NASDAQ HOLX) traded down $0.01 on Tuesday, hitting $43.55. The stock had a trading volume of 2,975,900 shares, compared to its average volume of 2,708,563. The stock has a market cap of $12,050.00, a PE ratio of 16.50, a PEG ratio of 2.01 and a beta of 0.95. The company has a current ratio of 0.79, a quick ratio of 0.61 and a debt-to-equity ratio of 0.79. Hologic has a 52 week low of $35.76 and a 52 week high of $46.80.
Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The company had revenue of $802.90 million during the quarter, compared to analyst estimates of $792.54 million. During the same quarter last year, the company earned $0.52 EPS. The firm’s revenue for the quarter was up 10.5% on a year-over-year basis. sell-side analysts predict that Hologic will post 2.13 EPS for the current fiscal year.
In other Hologic news, Director Elaine Ullian sold 9,282 shares of Hologic stock in a transaction on Monday, November 13th. The stock was sold at an average price of $40.50, for a total value of $375,921.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Karleen Marie Oberton sold 1,023 shares of Hologic stock in a transaction on Monday, November 20th. The stock was sold at an average price of $39.84, for a total value of $40,756.32. The disclosure for this sale can be found here. In the last three months, insiders sold 12,099 shares of company stock valued at $487,223. Corporate insiders own 0.79% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in HOLX. Royce & Associates LP purchased a new position in shares of Hologic in the 2nd quarter worth $908,000. Cambridge Investment Research Advisors Inc. purchased a new position in shares of Hologic in the 2nd quarter worth $213,000. Principal Financial Group Inc. boosted its stake in shares of Hologic by 4.5% in the 2nd quarter. Principal Financial Group Inc. now owns 452,260 shares of the medical equipment provider’s stock worth $20,524,000 after buying an additional 19,512 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in shares of Hologic by 0.4% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 20,803 shares of the medical equipment provider’s stock worth $944,000 after buying an additional 85 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. boosted its stake in shares of Hologic by 21.2% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 11,892 shares of the medical equipment provider’s stock worth $540,000 after buying an additional 2,080 shares during the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.